Prognostic value of 18F‐fluoroazomycin arabinoside PET/CT in patients with advanced non‐small‐cell lung cancer. Issue 11 (7th October 2015)

• Record Type: Journal Article
• Authors: Saga, Tsuneo; Inubushi, Masayuki; Koizumi, Mitsuru; Yoshikawa, Kyosan; Zhang, Ming‐Rong; Tanimoto, Katsuyuki; Horiike, Atsushi; Yanagitani, Noriko; Ohyanagi, Fumiyoshi; Nishio, Makoto
• Is Part Of: Cancer science. Volume 106:Issue 11(2015:Nov.)
• Page Start: 1554
• Page End: 1560
• Publication Date: 2015-10-07
• Subjects: 18F‐fluoroazomycin arabinoside (FAZA) -- 18F‐fluorodeoxyglucose (FDG) -- non‐small‐cell lung cancer -- positron emission tomography/computed tomography (PET/CT) -- prognosis; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.12771
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract : This study evaluated the prognostic value of positron emission tomography/computed tomography (PET/CT) using 18 F‐fluoroazomycin arabinoside (FAZA) in patients with advanced non‐small‐cell lung cancer (NSCLC) compared with 18 F‐fluorodeoxyglucose (FDG). Thirty‐eight patients with advanced NSCLC (stage III, 23 patients; stage IV, 15 patients) underwent FAZA and FDG PET/CT before treatment. The PET parameters (tumor‐to‐muscle ratio [T/M] at 1 and 2 h for FAZA, maximum standardized uptake value for FDG) in the primary lesion and lymph node (LN) metastasis and clinical parameters were compared concerning their effects on progression‐free survival (PFS) and overall survival (OS). In our univariate analysis of all patients, clinical stage and FAZA T/M in LNs at 1 and 2 h were predictive of PFS ( P = 0.021, 0.028, and 0.002, respectively). Multivariate analysis also indicated that clinical stage and FAZA T/M in LNs at 1 and 2 h were independent predictors of PFS. Subgroup analysis of chemoradiotherapy‐treated stage III patients revealed that only FAZA T/M in LNs at 2 h was predictive of PFS ( P = 0.025). The FDG PET/CT parameters were not predictive of PFS. No parameter was a significant predictor of OS. In patients with advanced NSCLC, FAZA uptake in LNs, but not in primary lesions, was predictive of treatment outcome. These results suggest the importance of characterization of LN metastases in advanced NSCLC patients. Abstract : This study evaluated the prognostic value of positron emission tomography/computed tomography (PET/CT) using 18F‐fluoroazomycin arabinoside (FAZA) in patients with advanced non‐small cell lung cancer (NSCLC). In patients with advanced NSCLC, FAZA uptake in LNs, but not in primary lesions, was predictive of treatment outcome.